Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study.
Gabriella RicciardelliGiuseppe GiannaccareAntonio Di ZazzoMarco CoassinVincenzo ScorciaMario R RomanoDavide AllegriniMichela CennamoMarco AntoniniFederico BernabeiAlberto MorelliRita MencucciPublished in: Eye (London, England) (2021)
Although further clinical evaluations are needed, according to our data the use of PVP-I 0.6% eye drop in the setting of AKC reduces the risk of SEIs as well as the resolution time of the disease.